Compare CRL & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | CWAN |
|---|---|---|
| Founded | 1947 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 7.2B |
| IPO Year | 1999 | 2021 |
| Metric | CRL | CWAN |
|---|---|---|
| Price | $214.20 | $24.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | ★ $198.27 | $25.09 |
| AVG Volume (30 Days) | 752.4K | ★ 6.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,857,601,000.00 | $731,368,000.00 |
| Revenue This Year | N/A | $31.67 |
| Revenue Next Year | $3.04 | $18.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 10.48 | ★ 61.88 |
| 52 Week Low | $144.26 | $15.74 |
| 52 Week High | $228.88 | $24.56 |
| Indicator | CRL | CWAN |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 67.84 |
| Support Level | $193.41 | $24.04 |
| Resistance Level | $228.64 | N/A |
| Average True Range (ATR) | 7.45 | 0.06 |
| MACD | 2.68 | 0.01 |
| Stochastic Oscillator | 92.13 | 100.00 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.